Research ExplorerPublicationsLoss of SFRP1 is associated with breast cancer progression a...

Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors.

Standard

Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. / Klopocki, Eva; Kristiansen, Glen; Wild, Peter J; Klaman, Irina; Castanos-Velez, Esmeralda; Singer, Gad; Stöhr, Robert; Simon, Ronald; Sauter, Guido; Leibiger, Haike; Essers, Lutz; Weber, Birgit; Hermann, Klaus; Rosenthal, André; Hartmann, Arndt; Dahl, Edgar.

In: INT J ONCOL, Vol. 25, No. 3, 3, 2004, p. 641-649.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Klopocki, E, Kristiansen, G, Wild, PJ, Klaman, I, Castanos-Velez, E, Singer, G, Stöhr, R, Simon, R, Sauter, G, Leibiger, H, Essers, L, Weber, B, Hermann, K, Rosenthal, A, Hartmann, A & Dahl, E 2004, 'Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors.', INT J ONCOL, vol. 25, no. 3, 3, pp. 641-649. <http://www.ncbi.nlm.nih.gov/pubmed/15289865?dopt=Citation>

APA

Klopocki, E., Kristiansen, G., Wild, P. J., Klaman, I., Castanos-Velez, E., Singer, G., Stöhr, R., Simon, R., Sauter, G., Leibiger, H., Essers, L., Weber, B., Hermann, K., Rosenthal, A., Hartmann, A., & Dahl, E. (2004). Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. INT J ONCOL, 25(3), 641-649. [3]. http://www.ncbi.nlm.nih.gov/pubmed/15289865?dopt=Citation

Vancouver

Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. INT J ONCOL. 2004;25(3):641-649. 3.

Bibtex

@article{9448788193784161bd8afb6f1016a6f7,
title = "Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors.",
abstract = "Aberrant activation of the Wnt signaling pathway plays an important role in the development of solid tumors such as breast and colon cancer. Secreted Frizzled-related protein 1 (SFRP1) is a negative regulator of the Wnt pathway. It has been described that SFRP1 mRNA is strongly down-regulated in breast cancer and a putative tumor suppressor function has been postulated. We have generated and characterized an SFRP1 specific antibody to analyze its expression on protein level and to investigate the association of SFRP1 expression with clinicopathological parameters and patient survival. Analysis of >2000 invasive breast tumors and 56 carcinoma in situ revealed similar frequencies of SFRP1 loss in these tumors (46% and 43% respectively). Therefore, we propose that loss of SFRP1 expression is an early event in breast tumorigenesis. SFRP1 expression was inversely correlated with tumor stage (p",
author = "Eva Klopocki and Glen Kristiansen and Wild, {Peter J} and Irina Klaman and Esmeralda Castanos-Velez and Gad Singer and Robert St{\"o}hr and Ronald Simon and Guido Sauter and Haike Leibiger and Lutz Essers and Birgit Weber and Klaus Hermann and Andr{\'e} Rosenthal and Arndt Hartmann and Edgar Dahl",
year = "2004",
language = "Deutsch",
volume = "25",
pages = "641--649",
journal = "INT J ONCOL",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

RIS

TY - JOUR

T1 - Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors.

AU - Klopocki, Eva

AU - Kristiansen, Glen

AU - Wild, Peter J

AU - Klaman, Irina

AU - Castanos-Velez, Esmeralda

AU - Singer, Gad

AU - Stöhr, Robert

AU - Simon, Ronald

AU - Sauter, Guido

AU - Leibiger, Haike

AU - Essers, Lutz

AU - Weber, Birgit

AU - Hermann, Klaus

AU - Rosenthal, André

AU - Hartmann, Arndt

AU - Dahl, Edgar

PY - 2004

Y1 - 2004

N2 - Aberrant activation of the Wnt signaling pathway plays an important role in the development of solid tumors such as breast and colon cancer. Secreted Frizzled-related protein 1 (SFRP1) is a negative regulator of the Wnt pathway. It has been described that SFRP1 mRNA is strongly down-regulated in breast cancer and a putative tumor suppressor function has been postulated. We have generated and characterized an SFRP1 specific antibody to analyze its expression on protein level and to investigate the association of SFRP1 expression with clinicopathological parameters and patient survival. Analysis of >2000 invasive breast tumors and 56 carcinoma in situ revealed similar frequencies of SFRP1 loss in these tumors (46% and 43% respectively). Therefore, we propose that loss of SFRP1 expression is an early event in breast tumorigenesis. SFRP1 expression was inversely correlated with tumor stage (p

AB - Aberrant activation of the Wnt signaling pathway plays an important role in the development of solid tumors such as breast and colon cancer. Secreted Frizzled-related protein 1 (SFRP1) is a negative regulator of the Wnt pathway. It has been described that SFRP1 mRNA is strongly down-regulated in breast cancer and a putative tumor suppressor function has been postulated. We have generated and characterized an SFRP1 specific antibody to analyze its expression on protein level and to investigate the association of SFRP1 expression with clinicopathological parameters and patient survival. Analysis of >2000 invasive breast tumors and 56 carcinoma in situ revealed similar frequencies of SFRP1 loss in these tumors (46% and 43% respectively). Therefore, we propose that loss of SFRP1 expression is an early event in breast tumorigenesis. SFRP1 expression was inversely correlated with tumor stage (p

M3 - SCORING: Zeitschriftenaufsatz

VL - 25

SP - 641

EP - 649

JO - INT J ONCOL

JF - INT J ONCOL

SN - 1019-6439

IS - 3

M1 - 3

ER -